An optimised Bcl‐3 inhibitor for melanoma treatment
At present, no other Bcl-3 inhibitors exist for clinical application in the field of oncology, and as a result, our novel findings provide a unique opportunity to develop a highly specific drug against malignant melanoma to meet an urgent clinical need.
Authors
- Eduard Chygorin
- Daniel Strand (ORCID: https://orcid.org/0000-0002-6113-4657)
- Kristofer Ahlqvist
- Susan Evans‐Axelsson (ORCID: https://orcid.org/0000-0002-4240-0550)
- Cecilia Persson (ORCID: https://orcid.org/0000-0001-6663-6536)
- Wondossen Sime (ORCID: https://orcid.org/0000-0001-9518-2457)
- Renée Daams (ORCID: https://orcid.org/0000-0001-6516-0580)
- Ramin Massoumi (ORCID: https://orcid.org/0000-0001-8875-6440)
- Karunakar Saamarthy
Institutions
- Lund University (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1111/bph.17467
- Citations
- 2
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- University of Pennsylvania
- European Commission
- Cancerfonden
- Carl Tryggers Stiftelse för Vetenskaplig Forskning
- Lunds Universitet
- Vetenskapsrådet
- European Research Council